A Case of Dexamethasone Intravitreal Implant Fragmentation During the Injection Procedure in Central Retinal Vein Occlusion.
10.3341/jkos.2013.54.6.982
- Author:
Sang Moon YOUN
1
;
Sung Jin PARK
;
Ho Young LEE
;
Sung Hyup LIM
;
Il Han YUN
Author Information
1. Department of Ophthalmology, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea. happytriad@gmail.com
- Publication Type:Case Report
- Keywords:
Dexamethasone intravitreal implant;
Fragmentation;
Ozurdex(R)
- MeSH:
Antibodies, Monoclonal, Humanized;
Dexamethasone;
Eye;
Humans;
Korea;
Macular Edema;
Retinal Vein;
Visual Acuity;
Bevacizumab
- From:Journal of the Korean Ophthalmological Society
2013;54(6):982-986
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: We report a case of dexamethasone intravitreal implant (Ozurdex(R); Allergan, Inc.) fragmentation during the injection procedure in macular edema due to central retinal vein occlusion. CASE SUMMARY: A 57-year-old man visited our hospital for visual disturbance in his right eye. The patient's best-corrected visual acuity was 0.02 in the right eye and 1.2 in the left eye. After fundus examination, the patient was diagnosed with central retinal vein occlusion with macular edema, thus bevacizumab was injected in the right eye. However, the macular edema did not improve, and a dexamethasone intravitreal implant was injected in the right eye. Immediately after the dexamethasone intravitreal implant injection, on fundus exam, the drug was observed to be fragmented into 3 pieces without any additional treatment. After 2 months, the patient's best-corrected visual acuity was 0.4 in the right eye and 1.2 in the left eye. Macular edema decreased according to optical coherence tomography. CONCLUSIONS: A case of dexamethasone intravitreal implant fragmentation during an injection procedure has not been previously reported in Korea. Although the drug fragmented, the treatment was effective without complications.
